Next Article in Journal
Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review
Next Article in Special Issue
Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association
Previous Article in Journal
Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer
Previous Article in Special Issue
Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment
Open AccessReview

Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses

Department of Hematology, Zealand University Hospital, Vestermarksvej 7-9, 4000 Roskilde, Denmark
Cancers 2020, 12(8), 2194; https://doi.org/10.3390/cancers12082194
Received: 30 June 2020 / Revised: 3 August 2020 / Accepted: 3 August 2020 / Published: 6 August 2020
(This article belongs to the Special Issue New Insights into Myeloproliferative Neoplasms)
The myeloproliferative neoplasms (MPNs) are acquired hematological stem cell neoplasms characterized by driver mutations in JAK2, CALR, or MPL. Additive mutations may appear in predominantly epigenetic regulator, RNA splicing and signaling pathway genes. These molecular mutations are a hallmark of diagnostic, prognostic, and therapeutic assessment in patients with MPNs. Over the past decade, next generation sequencing (NGS) has identified multiple somatic mutations in MPNs and has contributed substantially to our understanding of the disease pathogenesis highlighting the role of clonal evolution in disease progression. In addition, disease prognostication has expanded from encompassing only clinical decision making to include genomics in prognostic scoring systems. Taking into account the decreasing costs and increasing speed and availability of high throughput technologies, the integration of NGS into a diagnostic, prognostic and therapeutic pipeline is within reach. In this review, these aspects will be discussed highlighting their role regarding disease outcome and treatment modalities in patients with MPNs. View Full-Text
Keywords: myeloproliferative neoplasms; essential thrombocythemia; polycythemia vera; myelofibrosis; next generation sequencing; gene mutations; prognosis; outcome; treatment modalities; early treatment myeloproliferative neoplasms; essential thrombocythemia; polycythemia vera; myelofibrosis; next generation sequencing; gene mutations; prognosis; outcome; treatment modalities; early treatment
Show Figures

Figure 1

MDPI and ACS Style

Skov, V. Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. Cancers 2020, 12, 2194.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop